🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

518 results for “Cho” Clear

  1. NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 2 mab active

    1 trial

  2. NaCl 0.9%, GAMMA-OH 200 mg/ml, solution injectable (IV)

    Pari Pharma GmbH

    The study population includes adult ICU patients with a hospitalization of more than 48 hours. We have chosen to include patients with or without mechanical ventilation, as sleep disorders affect all ICU patients after 48 hours.

    phase 2 small molecule active

    1 trial

  3. OCALIVA, Placebo for Bezafibrate, Bezalip Mono, Placebo for Obeticholic Acid, Bezalip, OCALIVA

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  4. OPM-101

    Chongqing Precision Biotech Co., Ltd

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  5. Ocaliva 5 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Primary biliary cholangitis

    phase 2 small molecule active

    1 trial

  6. PBCAR20A

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin's Lymphoma, Relapsed

    phase 2 gene therapy completed

    1 trial

  7. PBGENE-DMD (IV)

    Chongqing Precision Biotech Co., Ltd

    Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

    phase 2 mab active

    1 trial

  8. PCN-101

    Chongqing Precision Biotech Co., Ltd

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  9. PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation

    The First People's Hospital of Lianyungang

    Locally Advanced Perihilar Cholangiocarcinoma

    phase 2 other active

    1 trial

  10. PDI-192

    Chongqing Precision Biotech Co., Ltd

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  11. PDI-320

    Chongqing Precision Biotech Co., Ltd

    Rosacea

    phase 2 small molecule active

    1 trial

  12. PLN-74809

    PLIANT THERAPEUTICS, INC.

    Primary Sclerosing Cholangitis

    phase 2 small molecule completed

    1 trial

  13. PRAX-222 - Initial Dose

    Chongqing Precision Biotech Co., Ltd

    SCN2A-DEE

    phase 2 small molecule active

    1 trial

  14. PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures

    phase 2 small molecule active

    1 trial

  15. Part A: 20 and 40 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  16. Part1:Recombinant two-component COVID-19 vaccine (CHO cell)

    Jian Li

    COVID-19

    phase 2 mab completed

    1 trial

  17. Pemazyre 4.5 mg tablets

    The George Institute

    locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements

    phase 2 small molecule active

    1 trial

  18. Pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 2 small molecule completed

    1 trial

  19. Placebo

    Universal Integrated

    Purpura, Schoenlein-Henoch

    phase 2 small molecule active

    1 trial

  20. Placebo for ACP-204 capsules

    Lacuna Pharma Pty Ltd

    Lewy Body Dementia Psychosis (LBDP)

    phase 2 small molecule active

    1 trial

  21. Placebo for ML-007C-MA bilayer tablet

    MapLight Therapeutics

    Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

    phase 2 small molecule active

    1 trial

  22. Placebo for TransCon CNP, TransCon CNP 3.9 mg CNP-38/vial, Navepegritide 2.8 mg CNP(89-126), Navepegritide 1.3 mg CNP(89-126)

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  23. Placebo to match ACP-204

    Lacuna Pharma Pty Ltd

    Alzheimer Disease psychosis

    phase 2 small molecule active

    1 trial

  24. Prednisone

    Nanjing Children's Hospital

    Henoch-Schoenlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources